Gilead buys remaining rights to cancer immunotherapy drug from partner Jounce - Silicon Valley Business Journal

📆 28/12/2022 22:00:00
📰 svbizjournal

⏱ Reading Time:
24 sec. here
2 min. at publisher
📊 Quality Score:
News: 13%
Publisher: 59%

Nigeria News News

Nigeria Nigeria Latest News,Nigeria Nigeria Headlines

$GILD buys out rights to early-stage $JNCE cancer drug as part of ongoing efforts to beef up its cancer drug pipeline.

Gilead Sciences Inc. will pay $67 million for the remaining rights to a cancer immunotherapy drug from partner Jounce Therapeutics Inc., a move to strengthen the Foster City-based drug maker's pipeline of potential cancer drugs.

GS-1811 is designed to selectively deplete immune system-suppressing T regulatory cells that infiltrate the area in and around tumors, giving the body's immune system a better chance at fighting off the cancer. "GS-1811, with its potential new pathway of activating the immune system, gives us the opportunity to potentially change the standard of care with a treatment works from inside cancerous cells to shrink solid tumors," said Dr.Richard Murray

Write Comment

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Nigeria Nigeria Latest News, Nigeria Nigeria Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Gilead buys remaining rights to cancer immunotherapy drug from partner Jounce - San Francisco Business Times$GILD buys out rights to early-stage $JNCE cancer drug as part of ongoing efforts to beef up its cancer drug pipeline.
Source: SFBusinessTimes - 🏆 78. / 68 Read more »

S.F. grocery delivery giant Instacart trims valuation - Silicon Valley Business JournalInstacart cut its meaty valuation back in March. Here's how much it's just trimmed it again. bayarea technews
Source: svbizjournal - 🏆 334. / 59 Read more »